Clinical Trials

Prostatic Neoplasms

NCT05896566 2026-02-24

PREcoopERA

231 enrolled

Breast Neoplasms

NCT05498272 2026-01-23

NePtune

32 enrolled

Prostatic Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

50 enrolled

Prostatic Neoplasms

NCT05982093 2025-05-22

SOLTI-2104

48 enrolled

Breast Neoplasms

NCT02278185 2025-05-11

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

19 enrolled 18 charts

Prostatic Neoplasms

NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

149 enrolled

Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03899077 2024-02-07

SAVE

202 enrolled

Prostatic Neoplasms

NCT05851547 2024-01-05

DEFINE

54 enrolled

Prostatic Neoplasms

NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

75 enrolled

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

NCT05557604 2022-09-28

STUNNIN

146 enrolled

Neoplasms, Prostatic Neoplasms

NCT02113553 2022-09-10

Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

45 enrolled

Breast Neoplasms

NCT05212857 2022-03-16

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

160 enrolled

Prostatic Neoplasms

NCT00090844 2021-01-28

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

49 enrolled 10 charts

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT04659551 2020-12-09

GIADA

43 enrolled

Breast Neoplasms

NCT02168062 2020-07-23

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

57 enrolled 27 charts

Prostate Adenocarcinoma

NCT02742675 2020-07-07

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

200 enrolled

Prostatic Neoplasms

NCT01790126 2020-03-11

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

90 enrolled 23 charts

Prostatic Neoplasms

NCT00444639 2019-11-22

Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

25 enrolled

Prostatic Neoplasms

NCT01374087 2019-09-18

ANABRAQ

32 enrolled 9 charts

Prostatic Neoplasms

NCT02005887 2019-05-29

TREND

51 enrolled 10 charts

Breast Cancer Invasive Nos

NCT01257425 2019-02-08

PAMIS

109 enrolled 22 charts

Prostatic Neoplasms

NCT00194792 2017-07-11

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

28 enrolled 9 charts